ANAHEIM, CA, USA — July 28, 2026 — Illumax, an innovative Chinese IVD manufacturer focused on single-test chemiluminescence, flow fluorometry and flow cytometry, made its appearance at ADLM 2026, the world’s premier conference for diagnostics and laboratory medicine, held at the Anaheim Convention Center from July 26 to 30 ADLM.
Against the backdrop of ADLM’s focus on clinical lab automation, biomarker innovation and accessible diagnostic workflows, Illumax brought its full portfolio of multimodal immune diagnostic systems, headlined by the X16 and X100 all-in-one analyzers. The two platforms integrate chemiluminescence, multiplex immunoassay and flow cytometry within a unified automated workflow, supporting both single-biomarker quantitation and multiplex panel testing from a single sample input. Built under the flexible “one registration, multiple configurations” NMPA pathway, X16 targets compact, mid-throughput lab and point-of-care settings, while X100 delivers robust throughput for core clinical laboratories, forming a scalable product matrix for diverse hospital and lab needs.
Complementing the flagship X-series, Illumax demonstrated its mature Lumiflx and Lumilite chemiluminescence platforms, including Lumiflx16 with direct primary tube loading and fully automated sample-to-result operation, alongside the compact Lumilite8 for emergency departments and decentralized testing scenarios. The supporting reagent panels on display covered cardiac markers, cytokines, autoantibodies and allergen profiles, highlighting the company’s end-to-end capability spanning core optical hardware, encoded microspheres, proprietary magnetic separation modules and matched assay kits.
Post time: Aug-03-2026
